Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434
Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 37,597 | $201,896 | +88% | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.50 | 47,620 | $23,810.00 | 191,340 | 2026-08-31 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 139,258 | $747,815 | 0.29% | |
| 2. | 63,065 | $338,660 | 0% | |
| 3. | 62,000 | $332,940 | 0% | |
| 4. | 58,460 | $313,930 | 0% | |
| 5. | 10,239 | $54,983 | 0% |